Bevacizumab prolongs survival in first-line colorectal cancer: Results of a phase III trial of bevacizumab in combination with bolus IFL as a first-line therapy in subjects with metastatic CRC. - Hurwitz,H.; Fehrenbacher,L.; Cartwright,T. (Proc Am Soc Clin Oncol, 2003)